Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.
3.

Retinoid receptors in the human endometrium and its disorders: a possible modulator of 17 beta-hydroxysteroid dehydrogenase.

Ito K, Suzuki T, Moriya T, Utsunomiya H, Sugawara A, Konno R, Sato S, Sasano H.

J Clin Endocrinol Metab. 2001 Jun;86(6):2721-7.

PMID:
11397877
4.
5.
6.

Retinoic acid (RA) regulates 17beta-hydroxysteroid dehydrogenase type 2 expression in endometrium: interaction of RA receptors with specificity protein (SP) 1/SP3 for estradiol metabolism.

Cheng YH, Yin P, Xue Q, Yilmaz B, Dawson MI, Bulun SE.

J Clin Endocrinol Metab. 2008 May;93(5):1915-23. doi: 10.1210/jc.2007-1536. Epub 2008 Feb 12.

7.

Expression analysis of estrogen-metabolizing enzymes in human endometrial cancer.

Smuc T, Rupreht R, Sinkovec J, Adamski J, Rizner TL.

Mol Cell Endocrinol. 2006 Mar 27;248(1-2):114-7. Epub 2005 Dec 6.

PMID:
16337331
8.

Overexpression of 17β-hydroxysteroid dehydrogenase type 1 increases the exposure of endometrial cancer to 17β-estradiol.

Cornel KM, Kruitwagen RF, Delvoux B, Visconti L, Van de Vijver KK, Day JM, Van Gorp T, Hermans RJ, Dunselman GA, Romano A.

J Clin Endocrinol Metab. 2012 Apr;97(4):E591-601. doi: 10.1210/jc.2011-2994. Epub 2012 Feb 22.

PMID:
22362820
9.

Expression of retinoic acid receptors in human endometrial carcinoma.

Tanabe K, Utsunomiya H, Tamura M, Niikura H, Takano T, Yoshinaga K, Nagase S, Suzuki T, Ito K, Matsumoto M, Hayashi S, Yaegashi N.

Cancer Sci. 2008 Feb;99(2):267-71. doi: 10.1111/j.1349-7006.2007.00684.x.

10.

Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17beta-estradiol.

Zeitoun K, Takayama K, Sasano H, Suzuki T, Moghrabi N, Andersson S, Johns A, Meng L, Putman M, Carr B, Bulun SE.

J Clin Endocrinol Metab. 1998 Dec;83(12):4474-80.

PMID:
9851796
11.

Estrogen receptors (alpha and beta) and 17beta-hydroxysteroid dehydrogenase type 1 and 2 in thyroid disorders: possible in situ estrogen synthesis and actions.

Kawabata W, Suzuki T, Moriya T, Fujimori K, Naganuma H, Inoue S, Kinouchi Y, Kameyama K, Takami H, Shimosegawa T, Sasano H.

Mod Pathol. 2003 May;16(5):437-44.

14.

Enzymes as modulators in malignant transformation.

Vihko P, Herrala A, Härkönen P, Isomaa V, Kaija H, Kurkela R, Li Y, Patrikainen L, Pulkka A, Soronen P, Törn S.

J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):277-83. Epub 2005 Feb 25.

PMID:
15860271
16.

The analyses of 17beta-hydroxysteroid dehydrogenase isozymes in human endometrial hyperplasia and carcinoma.

Utsunomiya H, Suzuki T, Kaneko C, Takeyama J, Nakamura J, Kimura K, Yoshihama M, Harada N, Ito K, Konno R, Sato S, Okamura K, Sasano H.

J Clin Endocrinol Metab. 2001 Jul;86(7):3436-43.

PMID:
11443221
17.

Expression of nuclear retinoic acid receptor and retinoid X receptor mRNA in the cornea and conjunctiva.

Bossenbroek NM, Sulahian TH, Ubels JL.

Curr Eye Res. 1998 May;17(5):462-9.

PMID:
9617539
18.

The N-terminal of the estrogen receptor (ERalpha) mediates transcriptional cross-talk with the retinoic acid receptor in human breast cancer cells.

Rousseau C, Pettersson F, Couture MC, Paquin A, Galipeau J, Mader S, Miller WH Jr.

J Steroid Biochem Mol Biol. 2003 Jul;86(1):1-14.

PMID:
12943740
19.

Differential growth regulation by all-trans retinoic acid is determined by protein kinase C alpha in human pancreatic carcinoma cells.

Rosewicz S, Brembeck F, Kaiser A, Marschall ZV, Riecken EO.

Endocrinology. 1996 Aug;137(8):3340-7.

PMID:
8754760
20.

9-Cis retinoic acid inhibits growth of breast cancer cells and down-regulates estrogen receptor RNA and protein.

Rubin M, Fenig E, Rosenauer A, Menendez-Botet C, Achkar C, Bentel JM, Yahalom J, Mendelsohn J, Miller WH Jr.

Cancer Res. 1994 Dec 15;54(24):6549-56.

Supplemental Content

Support Center